Search
forLearn
5 / 801 resultslearn PTD-DBM
learn PTT-6®
learn HT-B
learn TDM-105795
Research
5 / 1000+ resultsresearch Hopes and Limits of Adipose-Derived Stem Cells (ADSCs) and Mesenchymal Stem Cells (MSCs) in Wound Healing
ADSCs help in wound healing and skin regeneration but need more research for full understanding.
research MSCs and their exosomes: a rapidly evolving approach in the context of cutaneous wounds therapy
MSCs and their exosomes may speed up skin wound healing but need more research for consistent use.
research Regulation of pathophysiological and tissue regenerative functions of MSCs mediated via the WNT signaling pathway (Review)
The WNT signaling pathway is crucial for mesenchymal stem cells' function and therapy success.
research MSCs: Scientific Support for Multiple Therapies
Mesenchymal Stem Cells (MSCs) are promising for multiple therapies, but more research is needed to fully understand and optimize their use.
research MSCs, but not mesenchymal stem cells
MSCs should be called "master signaling cells" because they mainly help with cell communication and tissue repair.
Community Join
5 / 1000+ resultscommunity Microneedling and aloe vera to recruit stem cells.
Microneedling combined with aloe vera may stimulate dormant stem cells in hair loss areas. Minoxidil is also suggested for better results.
community mallia therapeutics 8T3 scd83 molecule for ffa/lpp mainly and aga
A user applied the 8T3 product for hair loss, targeting LPP and AGA, and plans to update on its effectiveness. The product uses a saline buffered phosphate vehicle, suitable for those intolerant to ethanolic vehicles.
community ET-02 Now Recruiting in Texas for Phase 1
Eirion Therapeutics is recruiting for phase 1 of ET-02 in Texas, which showed promising hair growth results in non-clinical studies. ET-02 demonstrated significantly more hair growth compared to Minoxidil.
community HLT Megathread on HMI-115 (key takeaways in comments)
HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.
community PTD-DBM Update: Q&A With Dr. Kang-Yell Choi
PTD-DBM is being explored for hair regrowth by targeting CXXC5, with clinical trials expected after pre-clinical studies. Users express anticipation and skepticism about its effectiveness.